ArriVent BioPharma Shares Rally 26% in 4 Days Since Other
ArriVent BioPharma announces Phase 1b results for firmonertinib in Cancer Cell, showing a 68% overall response rate for patients with EGFR PACC-mutant NSCLC.
ALFA USA News
Straight from the SEC filing
Every SEC filing by ArriVent BioPharma, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (19 Oct 2026). Not a valuation or a recommendation.
Down 35.6% over the last month ($17.94 on 19 Oct → $11.56 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $17.94 |
|---|---|
| 20 Oct | $18.85 |
| 21 Oct | $19.12 |
| 22 Oct | $19.20 |
| 23 Oct | $21.00 |
| 26 Oct | $15.36 |
| 27 Oct | $15.40 |
| 28 Oct | $15.73 |
| 29 Oct | $15.95 |
| 30 Oct | $14.87 |
| 2 Nov | $13.35 |
| 3 Nov | $13.02 |
| 4 Nov | $13.49 |
| 5 Nov | $12.23 |
| 6 Nov | $13.64 |
| 9 Nov | $14.16 |
| 10 Nov | $13.49 |
| 11 Nov | $13.51 |
| 12 Nov | $13.07 |
| 13 Nov | $13.01 |
| 16 Nov | $11.56 |
ArriVent BioPharma announces Phase 1b results for firmonertinib in Cancer Cell, showing a 68% overall response rate for patients with EGFR PACC-mutant NSCLC.
ArriVent BioPharma (AVBP) reports Phase 3 FURVENT trial for firmonertinib missed primary endpoint of PFS in NSCLC, despite achieving a 60% ORR at the 240mg dose.
Track ArriVent BioPharma, Inc. live
Get the next ArriVent BioPharma, Inc. SEC filing seconds after it lands.